BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...
The last time I spoke about Praxis Precision Medicines, Inc. (NASDAQ:PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback